v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Segment Information
The following table provides information about our single segment:

Three Months Ended March 31,
20262025
Operating Expenses:
   Significant components of research and development (R&D) expenses:
      Clinical trial expenses$747 $370 
      Manufacturing and related process development expenses507 414 
      Personnel-related expenses3,271 1,981 
   Significant components of general and administrative (G&A) expenses:
      Public company-related expenses3,016 1,200 
      Personnel-related expenses1,230 737 
      Intellectual property expenses302 107 
   All other R&D and G&A expenses208 212 
Total operating expenses9,281 5,021 
Loss from operations(9,281)(5,021)
Total other income, net38 310 
Net loss$(9,243)$(4,711)